ActivBiotics is committed to exploring the developmental potential of rifalazil and other novel rifamycin class antibacterials as novel medical treatments benefiting patients with vascular disease and other high value chronic and infectious disease markets.
R&D
To view this information, you must subscribe to Partneringtools.
Partnerships
To view this information, you must subscribe to Partneringtools.
Deals
To view this information, you must subscribe to Partneringtools.
Senior management
To view this information, you must subscribe to Partneringtools.
Board of directors
To view this information, you must subscribe to Partneringtools.
Head office
To view this information, you must subscribe to Partneringtools.